Prithviraj Bose, MD, a leukaemia expert from MD Anderson Cancer Center, shared some exciting news for polycythemia vera (PV) patients at the 2023 ASCO Annual Meeting. He discussed how ruxolitinib, a drug that blocks JAK1 and JAK2 enzymes, can improve survival without blood clots, lower the levels of JAK2 mutations and prevent PV from worsening.
Photo credit (2): MD Anderson Cancer Center
Breakthrough for Polycythemia Vera (PV) Treatment
Patients with polycythemia vera (PV) may benefit from a new treatment option, according to a summary of the 2023 ASCO Annual Meeting by Prithviraj Bose, MD. He reported that a PV-specific trial showed that ruxolitinib, a drug that inhibits JAK1 and JAK2 enzymes, can improve survival without thrombosis, lower the amount of JAK2 mutations and reduce the risk of disease progression in PV patients. This trial is the first to examine how ruxolitinib affects JAK2 mutational burden and its association with blood clots and clinical outcomes in PV patients. Ruxolitinib is an effective and safe drug for PV patients who do not respond well to hydroxyurea, another drug used to treat PV. These results indicate that ruxolitinib could be a valuable therapy to enhance the prognosis and quality of life of PV patients. See more information.
We are committed to keeping our MPN community updated and informed with the latest news and information about any relevant further discoveries in the MPN Field.
Stay tuned for more updates soon!
コメント